These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30047807)

  • 21. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
    Jin T; Bokarewa M; Amu S; Tarkowski A
    Clin Exp Rheumatol; 2009; 27(3):491-4. PubMed ID: 19604443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R; Moilanen E
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
    Timlin H; Bingham CO
    Expert Opin Biol Ther; 2014 Jul; 14(7):893-904. PubMed ID: 24720727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
    Inanc N; Direskeneli H
    Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of rheumatoid arthritis: Unraveling the conundrum.
    Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
    J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis.
    Tanaka Y; Senoo A; Fujii H; Baker D
    Expert Opin Drug Metab Toxicol; 2016; 12(3):319-26. PubMed ID: 26811250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG; den Broeder AA
    Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage.
    Klinkhoff A
    Drugs; 2004; 64(12):1267-83. PubMed ID: 15200343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biologic therapy with anti-TNFα in rheumathoid arthritis].
    Ferraccioli G
    Reumatismo; 2005; 57(4 Suppl):17-21. PubMed ID: 16385351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigational bispecific antibodies for the treatment of rheumatoid arthritis.
    Venetsanopoulou AI; Voulgari PV; Drosos AA
    Expert Opin Investig Drugs; 2024 Jul; 33(7):661-670. PubMed ID: 38698301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.